Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Geer

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Hardwarex|December 30, 2025
Lensless light guide-coupled LED illumination for low-cost microscopyFox Avery, Thomas Geer, Dirk Albrecht
Digestive Diseases (Basel, Switzerland)|May 16, 2006
Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in HeidelbergBernd Kasper, Birgit Kallinowski, Thomas Herrmann, et al.
Journal of Cancer Research and Clinical Oncology|May 16, 2018
Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional studyFlorian Nolte, Holger Nückel, Burkhard Schmidt, et al.
Oncology|July 16, 2005
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancerM Karthaus, Harald Ballo, Wolgang Abenhardt, et al.
Haematologica|March 3, 2009
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia veraSusanne Schnittger, Ulrike Bacher, Claudia Haferlach, et al.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
European Journal of Haematology|July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical RoutineSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|June 5, 2013
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple MyelomaBritta Auel, Hartmut Goldschmidt, Thomas Geer, et al.
Journal of Cancer Research and Clinical Oncology|February 16, 2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin careCarl Christoph Schimanski, Frank Staib, Thomas Göhler, et al.
British Journal of Cancer|October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Hardwarex|December 30, 2025
Lensless light guide-coupled LED illumination for low-cost microscopyFox Avery, Thomas Geer, Dirk Albrecht
Digestive Diseases (Basel, Switzerland)|May 16, 2006
Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in HeidelbergBernd Kasper, Birgit Kallinowski, Thomas Herrmann, et al.
Journal of Cancer Research and Clinical Oncology|May 16, 2018
Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional studyFlorian Nolte, Holger Nückel, Burkhard Schmidt, et al.
Oncology|July 16, 2005
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancerM Karthaus, Harald Ballo, Wolgang Abenhardt, et al.
Haematologica|March 3, 2009
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia veraSusanne Schnittger, Ulrike Bacher, Claudia Haferlach, et al.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
European Journal of Haematology|July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical RoutineSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|June 5, 2013
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple MyelomaBritta Auel, Hartmut Goldschmidt, Thomas Geer, et al.
Journal of Cancer Research and Clinical Oncology|February 16, 2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin careCarl Christoph Schimanski, Frank Staib, Thomas Göhler, et al.
British Journal of Cancer|October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
Pageof 3